Takeda Pharmaceutical Company Limited (4502) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 108 PAGES: 59

More Info
									                 Takeda Pharmaceutical Company Limited (4502) - Financial and
                              Strategic SWOT Analysis Review
        Reference Code: GDPH7835FSA                                                                                           Publication Date: MAR 2013

          1-1, Doshomachi 4-chome, Chuo-ku                   Phone             +81 6 62042111                   Revenue          1,508,932 (million JPY)
          Osaka, Osk                                         Fax               +81 6 62042880                   Net Profit       124,161 (million JPY)
          540-8645                                           Website           www.takeda.com                   Employees        30,305
                                                                               4502   [Tokyo         Stock                       Pharmaceuticals           &
          Japan                                              Exchange                                           Industry
                                                                               Exchange]                                         Healthcare

       Company Overview
       Takeda Pharmaceutical Company Limited (Takeda) is a pharmaceutical company. It focuses on the manufacture of ethical drugs
       and consumer health care products. The company manufactures and markets photographic chemicals, inorganic chemicals,
       vitamin bulks, test reagents and clinical diagnostics. Takeda markets its ethical drugs in over 100 countries worldwide through its
       subsidiaries in North America, Europe and Asia. The company operates through three reportable business segments, namely,
       Ethical Drug Business, Commercial Healthcare and Others. It operates production facilities in Osaka, Hikari, Italy, Ireland, China
       and Indonesia.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Takeda Pharmaceutical Company Limited, SWOT Analysis
         Yasuchika Hasegawa                  Chief Executive Officer                  Strengths                              Weaknesses
         Toyoji Yoshida                      Director
                                                                                      Extensive Range of Products            Product Recalls & Discontinued
         Frank Morich                        Chief Commercial Officer                                                        Projects
                                                                                      Sturdy Research and
         Tadataka Yamada                     Chief Medical Officer
                                                                                      Development Activities                 Weak Operational Efficiency
         Masato Iwasaki                      Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Strategic Business Initiatives         Competitive Landscape
         Takeda Pharmaceutical Company Limited
                                                                                      Demographics Trends                    Uncertain R&D Outcomes
        Share Price (JPY) as on 22-Mar-                                5,190
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (JPY)                                                     157.26         GlobalData
        Market Cap (million JPY)                                   4,097,246
        Enterprise Value (million JPY)                             4,437,141
        Shares Outstanding (million)                                     789
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 27, 2013         Takeda Announces Establishment Of New
                                                                                                           Organization, Change Of Organization Name
                                                                                      Feb 13, 2013         CommonMind Consortium Expands Public-
                                                                                                           Private Effort To Generate And Broadly Share
                                                                                                           Molecular Data On Neuropsychiatric Disease
                                                                                      Feb 04, 2013         Takeda Reports Revenue Of JPY1.2 Trillion
                                                                                                           For Nine Months Ended December 31, 2012
                                                                                      Jan 22, 2013         Takeda Establishes New Trading Company
                                                                                                           And Reinforces Business Structure In China
       Source: Annual Report, Company Website, Primary and Secondary                 Source: Annual Report, Company Website, Primary and Secondary Research,
       Research, GlobalData                                                          GlobalData




Takeda Pharmaceutical Company Limited (4502) - Financial and                                                                    Reference Code: GDPH7835FSA
Strategic SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Takeda Pharmaceutical Company Limited - Key Facts ...................................................................................................................... 5
       Takeda Pharmaceutical Company Limited - Key Employees ............................................................................................................. 6
       Takeda Pharmaceutical Company Limited - Key Employee Biographies ........................................................................................... 8
       Takeda Pharmaceutical Company Limited - Major Products and Services ........................................................................................ 9
       Takeda Pharmaceutical Company Limited - Pharmaceutical Pipeline Products Data ...................................................................... 11
          Takeda Pharmaceutical Company Limited, Pipeline Products by Therapy Area .......................................................................... 11
          Takeda Pharmaceutical Company Limited, Pipeline Products by Development Phase................................................................ 12
       Takeda Pharmaceutical Company Limited - History......................................................................................................................... 16
       Takeda Pharmaceutical Company Limited - Company Statement ................................................................................................... 22
       Takeda Pharmaceutical Company Limited - Locations And Subsidiaries......................................................................................... 26
          Head Office ................................................................................................................................................................................... 26
          Other Locations & Subsidiaries ..................................................................................................................................................... 26
       Takeda Pharmaceutical Company Limited - Key Manufacturing Facilities ....................................................................................... 32
       Section 2 – Company Analysis ......................................................................................................................................................... 33
       Takeda Pharmaceutical Company Limited - Business Description .................................................................................................. 33
       Takeda Pharmaceutical Company Limited - Corporate Strategy...................................................................................................... 34
       Takeda Pharmaceutical Company Limited - SWOT Analysis ........................................................................................................... 35
          SWOT Analysis - Overview........................................................................................................................................................... 35
          Takeda Pharmaceutical Company Limited - Strengths ................................................................................................................. 35
             Strength - Extensive Range of Products ................................................................................................................................... 35
             Strength - Sturdy Research and Development Activities ........................................................................................................... 35
             Strength - Geographical Landscape.......................................................................................................................................... 36
          Takeda Pharmaceutical Company Limited - Weaknesses ............................................................................................................ 36
             Weakness - Product Recalls & Discontinued Projects .............................................................................................................. 36
             Weakness - Weak Operational Efficiency ................................................................................................................................. 36
          Takeda Pharmaceutical Company Limited - Opportunities ........................................................................................................... 37
             Opportunity - Strategic Business Initiatives ............................................................................................................................... 37
             Opportunity - Demographics Trends ......................................................................................................................................... 37
             Opportunity - Strategic Acquisitions .......................................................................................................................................... 37
             Opportunity - New Product Launches and Approvals ................................................................................................................ 38
          Takeda Pharmaceutical Company Limited - Threats .................................................................................................................... 38
             Threat - Competitive Landscape ............................................................................................................................................... 38
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 38
             Threat - Stringent Government Regulations .............................................................................................................................. 39
       Takeda Pharmaceutical Company Limited - Key Competitors ......................................................................................................... 40
       Section 3 – Company Financial Ratios ............................................................................................................................................. 41
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 41
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 41
       Performance Chart ........................................................................................................................................................................... 43
       Financial Performance...................................................................................................................................................................... 43
       Financial Ratios - Interim Ratios....................................................................................................................................................... 44


Takeda Pharmaceutical Company Limited (4502) - Financial and                                                                                                     Reference Code: GDPH7835FSA
Strategic SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 45
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 46
          Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013.......................... 46
          Takeda Pharmaceutical Company Limited, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ......................... 47
          Takeda Pharmaceutical Company Limited, Medical Equipment, Deals By Year, 2007 to YTD 2013 ........................................... 48
          Takeda Pharmaceutical Company Limited, Medical Equipment, Deals By Type, 2007 to YTD 2013 ........................................... 49
       Takeda Pharmaceutical Company Limited, Recent Deals Summary ............................................................................................... 50
       Section 5 – Company’s Recent Developments ................................................................................................................................ 52
          Takeda Pharmaceutical Company Limited, Recent Developments .............................................................................................. 52
             Feb 27, 2013: Takeda Announces Establishment Of New Organization, Change Of Organization Name ................................ 52
             Feb 13, 2013: CommonMind Consortium Expands Public-Private Effort To Generate And Broadly Share Molecular Data On
             Neuropsychiatric Disease.......................................................................................................................................................... 52
             Feb 04, 2013: Takeda Reports Revenue Of JPY1.2 Trillion For Nine Months Ended December 31, 2012.........
								
To top